Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model
Abstract Background Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost impo...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | Radiation Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13014-019-1290-4 |
id |
doaj-bb749da0579d4f8192dd7ee9a9aa7cde |
---|---|
record_format |
Article |
spelling |
doaj-bb749da0579d4f8192dd7ee9a9aa7cde2020-11-25T03:27:11ZengBMCRadiation Oncology1748-717X2019-05-0114111110.1186/s13014-019-1290-4Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat modelJeroen Verhoeven0Julie Bolcaen1Valerie De Meulenaere2Ken Kersemans3Benedicte Descamps4Sam Donche5Caroline Van den Broecke6Tom Boterberg7Jean-Pierre Kalala8Karel Deblaere9Christian Vanhove10Filip De Vos11Ingeborg Goethals12Laboratory of Radiopharmacy, Ghent UniversityGhent University Hospital, Department of Nuclear MedicineGhent University Hospital, Department of Radiology and Medical ImagingGhent University Hospital, Department of Nuclear MedicineIBiTech-MEDISIP Ghent University, Department of Electronics and Information SystemsGhent University Hospital, Department of Nuclear MedicineGhent University Hospital, Department of PathologyGhent University Hospital, Department of Radiation OncologyGhent University Hospital, Department of NeurosurgeryGhent University Hospital, Department of Radiology and Medical ImagingIBiTech-MEDISIP Ghent University, Department of Electronics and Information SystemsLaboratory of Radiopharmacy, Ghent UniversityGhent University Hospital, Department of Nuclear MedicineAbstract Background Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. Method F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2) delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. Results When comparing the dose volume histograms, a significant difference was found exclusively between the D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. Conclusion In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory.http://link.springer.com/article/10.1186/s13014-019-1290-4GlioblastomaPET boostingFETFAZARadiotherapyPreclinical |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeroen Verhoeven Julie Bolcaen Valerie De Meulenaere Ken Kersemans Benedicte Descamps Sam Donche Caroline Van den Broecke Tom Boterberg Jean-Pierre Kalala Karel Deblaere Christian Vanhove Filip De Vos Ingeborg Goethals |
spellingShingle |
Jeroen Verhoeven Julie Bolcaen Valerie De Meulenaere Ken Kersemans Benedicte Descamps Sam Donche Caroline Van den Broecke Tom Boterberg Jean-Pierre Kalala Karel Deblaere Christian Vanhove Filip De Vos Ingeborg Goethals Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model Radiation Oncology Glioblastoma PET boosting FET FAZA Radiotherapy Preclinical |
author_facet |
Jeroen Verhoeven Julie Bolcaen Valerie De Meulenaere Ken Kersemans Benedicte Descamps Sam Donche Caroline Van den Broecke Tom Boterberg Jean-Pierre Kalala Karel Deblaere Christian Vanhove Filip De Vos Ingeborg Goethals |
author_sort |
Jeroen Verhoeven |
title |
Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model |
title_short |
Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model |
title_full |
Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model |
title_fullStr |
Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model |
title_full_unstemmed |
Technical feasibility of [18F]FET and [18F]FAZA PET guided radiotherapy in a F98 glioblastoma rat model |
title_sort |
technical feasibility of [18f]fet and [18f]faza pet guided radiotherapy in a f98 glioblastoma rat model |
publisher |
BMC |
series |
Radiation Oncology |
issn |
1748-717X |
publishDate |
2019-05-01 |
description |
Abstract Background Glioblastoma (GB) is the most common primary malignant brain tumor. Standard medical treatment consists of a maximal safe surgical resection, subsequently radiation therapy (RT) and chemotherapy with temozolomide (TMZ). An accurate definition of the tumor volume is of utmost importance for guiding RT. In this project we investigated the feasibility and treatment response of subvolume boosting to a PET-defined tumor part. Method F98 GB cells inoculated in the rat brain were imaged using T2- and contrast-enhanced T1-weighted (T1w) MRI. A dose of 20 Gy (5 × 5 mm2) was delivered to the target volume delineated based on T1w MRI for three treatment groups. Two of those treatment groups received an additional radiation boost of 5 Gy (1 × 1 mm2) delivered to the region either with maximum [18F]FET or [18F]FAZA PET tracer uptake, respectively. All therapy groups received intraperitoneal (IP) injections of TMZ. Finally, a control group received no RT and only control IP injections. The average, minimum and maximum dose, as well as the D90-, D50- and D2- values were calculated for nine rats using both RT plans. To evaluate response to therapy, follow-up tumor volumes were delineated based on T1w MRI. Results When comparing the dose volume histograms, a significant difference was found exclusively between the D2-values. A significant difference in tumor growth was only found between active therapy and sham therapy respectively, while no significant differences were found when comparing the three treatment groups. Conclusion In this study we showed the feasibility of PET guided subvolume boosting of F98 glioblastoma in rats. No evidence was found for a beneficial effect regarding tumor response. However, improvements for dose targeting in rodents and studies investigating new targeted drugs for GB treatment are mandatory. |
topic |
Glioblastoma PET boosting FET FAZA Radiotherapy Preclinical |
url |
http://link.springer.com/article/10.1186/s13014-019-1290-4 |
work_keys_str_mv |
AT jeroenverhoeven technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT juliebolcaen technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT valeriedemeulenaere technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT kenkersemans technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT benedictedescamps technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT samdonche technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT carolinevandenbroecke technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT tomboterberg technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT jeanpierrekalala technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT kareldeblaere technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT christianvanhove technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT filipdevos technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel AT ingeborggoethals technicalfeasibilityof18ffetand18ffazapetguidedradiotherapyinaf98glioblastomaratmodel |
_version_ |
1724588957838082048 |